These findings underscore the relevance of molecular modeling and structure-based drug design in identifying new therapeutic candidates for diabetes, complementing clinical research on DPP-4 inhibitors as adjunctive treatments in T1DM. Here, DPP4 is linked to diabetes mellitus.